Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

How accurate are stock forecasts?

Stock forecasts are based on technical and fundamental analysis but should not be considered as guaranteed predictions. Past performance does not guarantee future results.

How do I analyze DMAC stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate DMAC investment potential.

What is DMAC stock price today?

Get real-time DMAC stock price, historical data, and price charts on Financhill. Track DMAC performance with our advanced analysis tools.

Is DMAC a good investment?

Evaluate DMAC investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy DMAC stock?

To buy DMAC stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of DMAC?

View detailed market capitalization data and company valuation metrics for DMAC on our comprehensive analysis page.

What is the P/E ratio of DMAC?

Use our fundamental analysis tools to view DMAC P/E ratio and compare valuation metrics with industry peers.

What are DMAC earnings?

View DMAC earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

DiaMedica Therapeutics, Inc. Stock Predictions

$0.85 Entry Open - Fortune 1000 AI Tech in Demand

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi

Buy

DMAC
DiaMedica Therapeutics, Inc.

Last Price:

$8.80

Seasonality Move:

25.24%

7 Day Trial

ALL ACCESS PASS

$ 7

Missed $0.81? RAD Intel Now Open at $0.85/Share

DiaMedica Therapeutics, Inc. Stock Forecast

Over the next 52 weeks, DiaMedica Therapeutics, Inc. has on average historically risen by 21.8% based on the past 16 years of stock performance.
DiaMedica Therapeutics, Inc. has risen higher in 9 of those 16 years over the subsequent 52-week period, corresponding to a historical accuracy of 56.25%
Is DiaMedica Therapeutics, Inc. Stock Undervalued?

The current DiaMedica Therapeutics, Inc. [DMAC] share price is $8.78. The Score for DMAC is 64, which is 28% above its historic median score of 50, and infers lower risk than normal.
DMAC is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.

Will DiaMedica Therapeutics, Inc. Stock Go Up Next Year?

Over the next 52 weeks, DiaMedica Therapeutics, Inc. has on average historically risen by 21.8% based on the past 16 years of stock performance.

DiaMedica Therapeutics, Inc. Stock Rating

Buy

DiaMedica Therapeutics, Inc. (DMAC) is a Buy

Is DiaMedica Therapeutics, Inc. overpriced?

DiaMedica Therapeutics, Inc. has risen higher in 9 of those 16 years over the subsequent 52-week period, corresponding to a historical accuracy of 56.25%

DiaMedica Therapeutics, Inc. Stock Price History

Is DMAC stock going to rise?

Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and DMAC is experiencing slight selling pressure.

Stock Information

Stock Info

Exchange:

NASDAQ

Country:

United States

Industry:

Biotechnology

Sector:

Health Care

Type:

stock

Website:

diamedica.com

52-Week Data

52-Week High:

9.23

52-Week Low:

3.19

Prediction Charts

Market Cap:

457.2M

Price in USD:

8.78

Volume:

240.8K

Beta:

1.21

Technical Analysis

SMA50:

7.06

SMA100:

6.38

SMA200:

5.35

52-Wk Change:

63.5%

Stock Predictions

Is DiaMedica Therapeutics, Inc. stock public?

Yes, DiaMedica Therapeutics, Inc. is a publicly traded company.
What is the DiaMedica Therapeutics, Inc. stock quote today?

The DiaMedica Therapeutics, Inc. stock price is 8.78 USD today.
How to buy DiaMedica Therapeutics, Inc. stock online?

You can buy DiaMedica Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date	Opening	Closing	Minimum	Maximum
Nov-17	5.89	6.41	6.74	5.80
Nov-18	6.31	6.90	7.02	6.20
Nov-19	6.89	7.30	7.38	6.80
Nov-20	7.43	7.22	7.68	7.21
Nov-21	7.23	7.63	7.68	7.06
Nov-24	7.75	8.00	8.18	7.53
Nov-25	8.10	9.03	9.20	7.98
Nov-26	9.15	9.12	9.23	8.80
Nov-28	8.95	8.63	9.16	8.55
Dec-1	8.62	8.19	8.62	8.07
Dec-2	8.25	7.98	8.40	7.76
Dec-3	8.19	8.51	8.60	7.80
Dec-4	8.51	8.63	8.88	7.97
Dec-5	8.66	8.78	8.96	8.61

DiaMedica Therapeutics, Inc. Earnings

DiaMedica Therapeutics, Inc. Earnings Report: Per Share DiaMedica Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

DiaMedica Therapeutics, Inc. Forecast Revenue Growth

DiaMedica Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for DiaMedica Therapeutics, Inc. and historical quarterly revenue growth:

Analysts estimate an earnings decrease this quarter of $0.06 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.13 per share, and a decrease next year of $0.04 per share.

* DiaMedica Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.